Literature DB >> 7535184

Acute-phase protein response and survival duration of patients with pancreatic cancer.

J S Falconer1, K C Fearon, J A Ross, R Elton, S J Wigmore, O J Garden, D C Carter.   

Abstract

BACKGROUND: Current methods to predict survival duration of patients with pancreatic cancer are limited. The aim of this study was to determine whether certain nutritional indices and the acute-phase protein response are prognostic factors independent of disease stage for patients with unresectable pancreatic cancer.
METHODS: Variables at the time of diagnosis of 102 patients with unresectable pancreatic cancer were entered into a Cox's proportional hazards model. Included in the analysis were the serum concentration of C-reactive protein (CRP) and albumin, the extent of weight loss, age, sex, and disease stage (International Union Against Cancer criteria).
RESULTS: A multivariate analysis in which each factor was adjusted for the influence of the other factors revealed the patient age, disease stage, serum albumin, and serum CRP to be independent predictors of survival. The presence of an acute-phase protein response was the most significant independent predictors of survival duration. The median survival of those with an acute-phase protein response (CRP > 10 mg/L, n = 45) was 66 days compared with 222 days for those with no acute-phase protein response (n = 57, P = 0.001, Mann-Whitney U test).
CONCLUSION: The acute-phase protein response is a useful prognostic indicator for patients with unresectable pancreatic cancer. Moreover, the metabolic disturbances associated with an acute-phase protein response of patients with pancreatic cancer may be a worthwhile therapeutic target.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7535184     DOI: 10.1002/1097-0142(19950415)75:8<2077::aid-cncr2820750808>3.0.co;2-9

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  82 in total

1.  Enhanced psychosocial well-being following participation in a mindfulness-based stress reduction program is associated with increased natural killer cell activity.

Authors:  Carolyn Y Fang; Diane K Reibel; Margaret L Longacre; Steven Rosenzweig; Donald E Campbell; Steven D Douglas
Journal:  J Altern Complement Med       Date:  2010-05       Impact factor: 2.579

2.  Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas.

Authors: 
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

3.  Association between plasma plasminogen activator inhibitor-1 and survival in colorectal cancer. Measuring C reactive protein concentrations may be more useful.

Authors:  N Sattar; D C McMillan
Journal:  BMJ       Date:  1998-09-12

4.  The prognostic role of inflammation and hormones in patients with metastatic cancer with cachexia.

Authors:  Cemil Bilir; Huseyin Engin; Murat Can; Yasemin Bakkal Temi; Derya Demirtas
Journal:  Med Oncol       Date:  2015-02-01       Impact factor: 3.064

5.  Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma.

Authors:  E J Clark; S Connor; M A Taylor; K K Madhavan; O J Garden; R W Parks
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

Review 6.  A review of the application of inflammatory biomarkers in epidemiologic cancer research.

Authors:  Darren R Brenner; Dominique Scherer; Kenneth Muir; Joellen Schildkraut; Paolo Boffetta; Margaret R Spitz; Loic Le Marchand; Andrew T Chan; Ellen L Goode; Cornelia M Ulrich; Rayjean J Hung
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-06-24       Impact factor: 4.254

7.  The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer.

Authors:  D A C Deans; B H Tan; S J Wigmore; J A Ross; A C de Beaux; S Paterson-Brown; K C H Fearon
Journal:  Br J Cancer       Date:  2009-01-13       Impact factor: 7.640

8.  Evaluation of DNA ploidy in relation with established prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.

Authors:  Nikolas Tsavaris; Nicolaos Kavantzas; Kostantinos Tsigritis; Ioannis D Xynos; Nikitas Papadoniou; Andreas Lazaris; Christos Kosmas; George Agrogiannis; Anna Dokou; Evangelos Felekouras; Efstathios Antoniou; Aris Polyzos; John Sarantonis; Heracles Tsipras; Gavrilos Karatzas; Alexandros Papalambros; Efstratios S Patsouris
Journal:  BMC Cancer       Date:  2009-07-31       Impact factor: 4.430

9.  Plasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer.

Authors:  R J E Skipworth; D A C Deans; B H L Tan; K Sangster; S Paterson-Brown; D A Brown; M Hunter; S N Breit; J A Ross; K C H Fearon
Journal:  Br J Cancer       Date:  2010-01-26       Impact factor: 7.640

10.  Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function.

Authors:  Jeannine Bachmann; Knut Ketterer; Christiane Marsch; Kerstin Fechtner; Holger Krakowski-Roosen; Markus W Büchler; Helmut Friess; Marc E Martignoni
Journal:  BMC Cancer       Date:  2009-07-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.